250+ investors that invest in your industry and stage
Get 250+ investors tailored to your startup
  • Invest in your industry and stage
  • Emails & contact info included
  • Excel and CSV export
  • Automatically
Trusted by 3,000+ startups

Top 5 Beauty Startup Investors in Switzerland

A list of 5 angel investors and VC funds that invest in Beauty startups based in Switzerland. We rank investors based on the number of investments they made in Beauty companies from Switzerland. We update this investor list every month.

Top 5 Beauty Startup Investors in Switzerland

Investor Beauty Switzerland investments
Ertan Wittwer 2
Yellowstone Holding 1
UZH Life Sciences Fund 1
Zürcher Kantonal Bank 1
Giammaria Giuliani 1
Find investors that fund startups like yours. Automatically.
Our algorithm will find investors that invest in your industry, stage, and geography.
Investor list
Ertan Wittwer Angel · Munich, Bayern, Germany
Ertan Wittwer is the Founder and Board Member bestsmile. He attended BBZ Uzwil.
Show more
Investment focus
  • Health Care, Water, Beauty
  • Seed, Angel, Pre-Seed
  • Switzerland, United States
Portfolio highlights
  • Akina — Akina is developing the future of gamified digital healthcare to benefit individuals with chronic diseases around the world.
  • Noriware — Noriware wants to revolutionize the packaging industry by offering a truly sustainable, home-compostable alternative to traditional plastic, through unlocking the potential of seaweed. In doing so, we want to be the leader in transparency to motivate the industry to become more sustainable.
  • Alpine White — Alpine White is a healthcare startup that manufactures personal care products and treatments for its consumers. They exist to keep teeth healthy and white through great products and services that empower people to feel confident and feel good.
Yellowstone Holding VC Fund
Yellowstone Holding promoting new innovative products or technologies from Switzerland to the Asia market via our strong connections.
Show more
Investment focus
  • Beauty, Cosmetics, Navigation
  • Series A, Series B
  • Switzerland
Portfolio highlights
  • CUTISS — CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns.
  • Medyria — Medyria is a Swiss medtech startup that engineers technologies for cardiovascular catheter navigation and sensing. They develop a unique guiding and sensing medical device based on proprietary Blood Flow Velocity Sensor technology. The TrackCath System is designed to be cost-effective and safe during EVAR procedures.Medyria's goal is todevelop devices that enable safer and more effective endovascular procedures. It was founded in 2014 and is based in Winterthur, Zurich, Switzerland.
UZH Life Sciences Fund VC Fund · Zürich, Zurich, Switzerland
The UZH Life Sciences Fund involves two equal partners: the UZH Foundation and the Novartis Venture Fund. It seeks donations from private individuals, foundations and companies for the strategic priorities of the University of Zurich.
Show more
Investment focus
  • Health Care, Biotechnology, Medical Device
  • Funding Round, Seed, Convertible Note
  • Switzerland
Portfolio highlights
  • Occlufit — Occlufit is an occluder device that conforms to complex geometries and provides immediate sealing of cardiovascular defects.
  • Navignostics — Navignostics combines highly multiplex tumor imaging with advanced data analytics for personalized cancer treatments.
  • ImmunOs Therapeutics — ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease.
Zürcher Kantonal Bank VC Fund · Zürich, Zurich, Switzerland · 18 investments in the past 12 months
Zürcher Kantonalbank - as an independent, incorporated public-law institution - is wholly owned by the canton of Zurich.
Show more
Investment focus
  • Health Care, Medical Device, Biotechnology
  • Seed, Series A, Funding Round
  • Switzerland, Japan, Spain
Portfolio highlights
  • DataHow — DataHow is specialized in data analytics and bioprocess modeling
  • Drone Harmony AG — Drone Harmony was founded in 2016 by a team of problem solvers with a passion for drones, software and automation. From their very early days, they have set out to tackle the mathematical and engineering challenges of enabling cost-effective deployment of drone technology in industries, where existing technologies were unable to deliver.DroneHarmony reinvents the way people fly drones commercially. Its 3D flight planning software turns anyone with a drone into an inspection professional. Sophisticated algorithms reduce complex industrial inspection tasks to automated and scalable workflows.
  • Synthara Technologies — Synthara is a Zurich-based artificial intelligence (AI) company that provides system-level solutions for businesses to enhance their products or services with smart features. The company portable and wearable gadgets such as virtual reality headsets, small wireless monitoring cameras, sensor networks, have limited smart features because computingpowerful algorithms cannot be run on them. Synthara IPs provide server-class performance with an extremely low energy requirement for neural networks (10 TOPs/Watt).
Giammaria Giuliani Angel
Giammaria Giuliani
Show more
Investment focus
  • Beauty, Cosmetics
  • Series A, Series B
  • Switzerland
Portfolio highlights
  • CUTISS — CUTISS AG can now bio-engineer large quantities of individually customized human skin grafts, denovoSkin™, starting off from a very small piece of healthy patient’s skin. Because of its intrinsic characteristics, denovoSkin™ is expected to result in a minimally scarring outcome after transplantation. denovoSkin™ received a Swissmedic, EMA and FDAOrphan drug designation for the treatment of burns.
Investors by industry
Investors by country
Investors in Switzerland by industry